Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis1

Adenovirus (Ad) gene therapy has been proposed as a drug-delivery system for the targeted administration of protein-based therapies, including growth factors and biological response modifiers. However, inflammation associated with Ad transduction has raised concern about its safety and efficacy in acute inflammatory diseases. In the present report, intratracheal and i.v. administration of a first-generation adenoviral recombinant (E1,E3 deleted) either containing an empty cassette or expressing the anti-inflammatory cytokines viral or human IL-10 (IL-10) was administered to mice subjected to zymosan-induced multisystem organ failure or to acute necrotizing pancreatitis. Pretreatment of mice with the intratracheal instillation of Ad expressing human IL-10 or viral IL-10 reduced weight loss, attenuated the proinflammatory cytokine response, and reduced mortality in the zymosan-induced model, whereas pretreatment with a control adenoviral recombinant did not significantly exacerbate the response. Pretreatment of mice with pancreatitis using adenoviral vectors expressing IL-10 significantly reduced the degree of pancreatic and liver injury and liver inflammation when administered systemically, but not intratracheally. We conclude that adenoviral vectors can be administered prophylactically in acute inflammatory syndromes, and expression of the anti-inflammatory protein IL-10 can be used to suppress the underlying inflammatory process.

[1]  O. Moine,et al.  Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. , 2001, Gastroenterology.

[2]  L. Moldawer,et al.  Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Moldawer,et al.  Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation , 2000, Gene Therapy.

[4]  S. Pestka,et al.  A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin 10 , 2000, The Journal of experimental medicine.

[5]  L. Moldawer,et al.  TNF-α Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung1 , 2000, The Journal of Immunology.

[6]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[7]  K. Propert,et al.  A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. , 1999, Human gene therapy.

[8]  J. V. D. van der Meer,et al.  Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. , 1999, Cytokine.

[9]  R. Brown,et al.  p53-oriented cancer therapies: current progress. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Devière,et al.  Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice , 1998, Gut.

[11]  D. Curiel,et al.  Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. , 1998, Human gene therapy.

[12]  J. Cone,et al.  Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS) , 1998 .

[13]  H. Perlman,et al.  Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. , 1997, Circulation.

[14]  R. Crystal,et al.  Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors , 1997 .

[15]  A. Shaked,et al.  Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. , 1997, The Journal of surgical research.

[16]  M. Ng.  Is gene therapy in cystic fibrosis a realistic expectation , 1996 .

[17]  S. Ashley,et al.  Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. , 1996, Surgery.

[18]  P. Hu,et al.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. , 1995, The New England journal of medicine.

[19]  J. Devière,et al.  Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. , 1995, Gastroenterology.

[20]  F. Graham,et al.  Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.

[21]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[22]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Mosmann,et al.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors , 1991, The Journal of experimental medicine.

[25]  T. Mosmann,et al.  IL-10, a novel growth cofactor for mature and immature T cells. , 1990, Journal of immunology.

[26]  W. Flynn,et al.  Development of a bacteria-independent model of the multiple organ failure syndrome. , 1989, Archives of surgery.

[27]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[28]  R. Goris,et al.  Multiple-organ failure and sepsis without bacteria. An experimental model. , 1986, Archives of surgery.

[29]  D. Longnecker,et al.  Acute hemorrhagic pancreatitis (massive necrosis) with fat necrosis induced in mice by DL-ethionine fed with a choline-deficient diet. , 1975, The American journal of pathology.

[30]  T. Hollon.  Researchers and regulators reflect on first gene therapy death , 2000, Nature Medicine.

[31]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[32]  N. McElvaney.  Is gene therapy in cystic fibrosis a realistic expectation? , 1996, Current opinion in pulmonary medicine.

[33]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.

[34]  Ronald G. Crystal,et al.  The gene as the drug , 1995, Nature Medicine.

[35]  W. Anderson,et al.  Human gene therapy. , 1993, Annual review of biochemistry.

[36]  L. Ferrell,et al.  Acute experimental hemorrhagic-necrotizing pancreatitis induced by feeding a choline-deficient, ethionine-supplemented diet. Methodology and standards. , 1992, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.